Non-ownership Filings
| Eneboparatide Phase III trial met primary endpoint | Mar. 17, 2025 |
| Imfinzi approved in EU for limited-stage SCLC | Mar. 17, 2025 |
| AstraZeneca to acquire EsoBiotec | Mar. 17, 2025 |
| Imfinzi improved EFS in early-stage gastric cancer | Mar. 07, 2025 |
| Total Voting Rights | Mar. 03, 2025 |
| Imfinzi recommended for EU approval for AEGEAN | Mar. 03, 2025 |
| Enhertu recommended in EU in post-ET breast cancer | Feb. 28, 2025 |
Ownership Update Filings
| Holding(s) in Company | Mar. 12, 2025 |
| Director/PDMR Shareholding | Mar. 07, 2025 |
| Director/PDMR Shareholding | Mar. 06, 2025 |
| Director/PDMR Shareholding | Mar. 05, 2025 |
| Holding(s) in Company | Feb. 18, 2025 |
| Director/PDMR Shareholding | Nov. 20, 2024 |
| Director/PDMR Shareholding | Nov. 15, 2024 |